Business Context and Reporting Period
Company: Inotek Pharmaceuticals Corporation (Note: Metadata listed "Rocket Pharmaceuticals," but the filing text identifies the registrant as Inotek Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2015
Reporting Period: Events occurring on February 23, 2015, regarding the completion of capital raising activities and debt repayment.
Key Financial Metrics and Capital Structure
- Convertible Notes Offering: Completed sale of $20.0 million aggregate principal amount of 5.0% Convertible Senior Notes due 2020. Net proceeds were approximately $18.6 million.
- Common Stock Offering: Completed sale of 6,667,000 shares of common stock. Net proceeds were approximately $35.0 million.
- Total Net Proceeds: Approximately $53.6 million combined from both offerings.
- Debt Repayment: Used approximately $5.8 million of net proceeds to repay and terminate prior notes payable agreements with Horizon Technology Finance Corporation and Fortress Credit Co LLC.
- Debt Terms: New Notes bear 5.0% interest payable semi-annually, maturing February 15, 2020. Initial conversion price is approximately $6.30 per share.
Material Changes Versus Prior Period
- Capitalization: Significant increase in cash liquidity through the dual offering of debt and equity.
- Debt Reduction: Elimination of previous secured debt obligations (Loan A and Loan B) totaling approximately $5.8 million in principal and interest payments.
- Interest Rate Environment: Replacement of prior debt carrying an 11.0% annual interest rate with new convertible notes at 5.0%.
- Overallotment Options: Underwriters hold 30-day options to purchase an additional $3.0 million in Notes and 1,000,050 shares of Common Stock. As of the report date, these options have not been exercised.
Guidance, Outlook, and Use of Proceeds
Management intends to use the remaining net proceeds for the following specific clinical and corporate purposes:
- Phase 3 Trial: Approximately $17.0 million for the first Phase 3 pivotal trial for trabodenoson monotherapy.
- Phase 2 Trial: Approximately $9.0 million for a Phase 2 trial for the FDC product candidate and commercial formulation development.
- Proof-of-Concept: Approximately $6.0 million for clinical trials targeting optic neuropathies and degenerative retinal diseases.
- General: Remainder for working capital and general corporate purposes.
Risks and Contingencies: The Company notes it cannot predict with certainty the actual amounts spent on the uses set forth. The Indenture includes limitations on incurring additional indebtedness, issuing preferred stock, and entering into certain merger transactions. Holders may require repurchase of Notes upon certain fundamental changes.
Investor Verification Checklist
- Verify the exercise status of the underwriters' 30-day overallotment options for both the Notes and Common Stock.
- Confirm the exact cash balance remaining after the $5.8 million debt repayment and initial clinical trial expenditures.
- Review the specific terms of the "Make-Whole Fundamental Change" and "Interest Make-Whole Payment" provisions in the Indenture (Exhibit 4.1).
- Monitor the status of the warrants held by Horizon and Fortress, which remain exercisable until June 28, 2023.
- Track the progress and costs of the trabodenoson Phase 3 trial against the allocated $17.0 million budget.